Sex Differences in Opioid Analgesia and Addiction: Interactions among Opioid Receptors and Estrogen Receptors

Abstract

Opioids are widely used as the pain reliever and also notorious for being addictive drugs. Sex differences in the opioid analgesia and addiction have been reported and investigated in human subjects and animal models. Yet, the molecular mechanism underlying the differences between males and females is still unclear. Here, we reviewed the literature describing the sex differences in analgesic responses and addiction liabilities to clinically relevant opioids. The reported interactions among opioids, estrogens, opioid receptors, and estrogen receptors are also evaluated. We postulate that the sex differences partly originated from the crosstalk among the estrogen and opioid receptors when stimulated by the exogenous opioids, possibly through common secondary messengers and the downstream gene transcriptional regulators.

Keywords

Sex differences Opioid analgesia Opioid addiction Opioid receptors Estrogen receptors

Review

Introduction

Opioids are potent analgesics used to treat acute and chronic pain, and also notorious for their potential to cause addiction [1 –4]. Gender differences in the experience of clinical and experimental pain [5 –7] and the susceptibility to opioid addiction [8] have been reported. General observations suggest that there are more adult men than women involved in illicit drug abuse [9]. However, this contrasts to the clinical and animal studies indicating that females are more susceptible to drug abuse problem than males [10]. Besides the sociocultural factors, there must be true differences between the biological differences that influence drug abuse and pain perception, and estrogen has been proposed to be one of the key players [11,12].

Sex differences in opioid analgesia and addiction

Population-based studies suggest that women are more likely to experience chronic pain syndromes and report more severe pain at a higher frequency than men [13 –19]. Human studies indicate that females and males have similar thresholds for cold and ischemic pain [20,21], while pressure pain thresholds are lower in females than males [22,23]. Females tolerate less thermal pain (cold, heat) and pressure than males [24 –26], but this is not the case for tolerance to ischemic pain, which is comparable in both genders [27,28]. Based on a review of the available literature published between 1966 and 1998, Miaskowski and Levine suggest that opioids are better analgesics for women [29]. A Chinese population study conducted in southern Taiwan also shows that females consume significantly less morphine via patient-controlled analgesia than males during the first three postoperative days [30]. However, the majority of more recent studies comparing gender report that the potency and efficacy of morphine administered systemically is higher in males than in females against a variety of nociceptive modalities [31 –33]. The controversy might be due to that earlier studies did not correct for the body weight differences between men and women. In addition, there are sex differences in reporting pain and seeking pain relief, and health care providers make unwarranted psychogenic attributions regarding pain in female but not male [7,34 –36].

A profile of a heroin-addiction epidemic showed that 74 percent of the addicts are males [37]. In the United States, the past year and life time rates of heroin use are higher among men (men=0.2% vs. women = 0.1%; 2.3% vs. 0.8%, respectively), while equivalent rates of men and women are reported to inject heroin (42.0% vs. 40.7%) [8]. Among adolescent drug users administrated during 2002–2003 in the National Survey on Drug Use and Health, females are 3.91 times more likely to inject heroin than males [38]. Gender differences in the clinical profiles of opioid-dependent individuals have been observed in substance use severity, craving, medical conditions, and impairment in associated areas of functioning. Craving for opioids is significantly higher among women, and women have higher drug, employment, family, medical, and psychiatric Addiction Severity Index composite scores [8]. Among patients entering the maintenance program in Italy, there seems to be an emerging pattern of males who tend to use heroin as their opiate of choice, and are more likely to combine it with cannabis, while females are more likely to using street methadone, with adjunctive use of ketamine, benzodiazepines, hypnotic drugs and/or amphetamines [39]. Moreover, women are at higher risk of abusing opioids through initial prescription painkiller use, and later resort to street methadone to cope with prescription pain killer addiction [39]. Analysis from the U.S. indicates that opioid-addicted women work less and use more cocaine than their male counterparts [40]. The use of drugs of abuse in women may be influenced by psychosocial and hormonal factors, such as psychiatric comorbidity (a higher rate of anxiety disorders) [41 –44], more distressing drug-related environment, lower rate of antisocial personality traits [45], and estrogen-regulated neuroendocrine functions [12,39,46]. Sex differences in opioid analgesia and addiction in human and animals have been investigated extensively, and clinically-relevant representative studies are listed in Tables 1 and 2. Effects of opioids are inconsistent among different studies and species, which might result from different genetic backgrounds, ages of the subjects, doses of the opioids used, and assays or end points of the measurements.

Table 1

Sex differences in opioid analgesia and addiction in human

Opioid	Receptor	Model	Effect	Reference
Buprenorphine	ORL1 agonist	Postoperative pain	M < F	[47 –49]
	MOR partial agonist
	KOR antagonist
Butorphanol	MOR partial agonist	Acute injury	M = F	[50]
	KOR agonist	Thermal, pressure, and ischemic pain (experimental)	M = F	[51]
		Postoperative dental surgery	M < F	[52]
		Cold-water stimulus (experimental)	M > F	[53]
Fentanyl	MOR agonist	Postoperative pain	M < F	[54]
			M = F	[55]
Ketobemidone	MOR agonist	Postoperative pain	M = F	[56]
	NMDA antagonist
Methadone	MOR agonist	Cancer pain	M = F	[57]
Morphine	MOR agonist	Acute injury	M > F	[50]
	KOR agonist	Thermal, pressure, and ischemic pain (experimental)	M = F	[51]
	DOR agonist
		Postoperative pain	M > F	[32,33]
			M = F	[58 –60]
			M < F	[30,61 –64]
Nalbuphine	KOR agonist	Postoperative pain	M = F	[65]
	MOR antagonist	Postoperative dental surgery	M < F	[52,66]
Pentazocine	KOR agonist	Acute pain (experimental)	M = F	[67,68]
	MOR partial agonist		M < F	[69]
		Postoperative dental surgery	M < F	[70]
Pethidine	MOR agonist	Postoperative pain	M = F	[60,71]
	KOR agonist
Heroin	MOR agonist	Addiction epidemic	M > F	[8,37]
	KOR agonist	Adolescent drug users	M < F	[38]
	DOR agonist

Table 2

Sex differences in opioid analgesia and addiction in animals

Opioid	Receptor	Species	Model	Effect	Reference
Buprenorphine	0RL1 agonist	Rat	Hot plate	M = F	[72]
	MOR partial agonist		Tail withdrawa	M > F	[73 –75]
	KOR antagonist
				M = F	[72]
			Temporal summation (thermal stimulus / tail withdrawal)	M > F	[76]
Butorphanol	MOR partial agonist	Rat	Capsaicin-induced hyperalgesia (Tail withdrawal)	M = F	[77]
	KOR agonist		Temporal summation (thermal stimulus / tail withdrawal)	M > F	[76]
Fentanyl	MOR agonist	Rat	Tail flick	M = F	[78]
Methadone	MOR agonist	Rat	Tail flick	M > F	[79]
Morphine	MOR agonist	Rat	Abdominal constriction	M > F	[80,81]
	KOR agonist		Hot plate	M > F	[81 –86]
	DOR agonist			M < F	[87]
			Tail flick	M > F	[76,81,88 –94]
				M = F	[95]
			Tail withdrawal	M > F	[74,75,85,86]
			Temporal summation (thermal stimulus / tail withdrawal)	M > F	[96]
		Mouse	Hot plate	M > F	[97 –99]
			Tail Flick	M > F	[100]
			Tail Withdrawal	M > F	[101,102]
				M = F	[101]
				M < F	[101]
Nalbuphine	KOR agonist	Rat	Tail withdrawa	M > F	[74,103,104]
	MOR antagonist
Heroin	MOR agonist	Rat	Acquisition of self-administration	M < F	[105 –107]
	KOR agonist
	DOR agonist

Factors contributing to sex differences in drug abuse include pharmacokinetics, behavioral phenotypes for drug abuse vulnerability, sensitivity to aversive properties of drugs, puberty and adolescence, and genetic factors beyond hormones as reviewed by Wetherington [108]. Given the ubiquitous actions and gender differences of sex hormones in the central nervous system, many investigators have attempted to relate sex differences in opioid analgesia to gonadal hormone levels [73,80 –82,88 –93,100,109 –118]. Yet, the neurological and cellular mechanisms underlying the sexually dimorphic analgesic and addictive responsiveness to opioids remain poorly understood [31].

Estrogen regulation of opioid receptors

The analgesic effects and addiction liability of opioids are mediated by opioid receptors. Based on the molecular and pharmacological properties, three conventional opioid receptors – μ (MOR), δ (DOR), and κ (KOR) - have been characterized [119]. A non-opioid branch of opioid receptors, opioid receptor-like 1 (ORL1) receptor, also known as the nociceptin/orphanin FQ peptide (NOP) receptor, has also been identified and displays pharmacological profiles distinct from those of conventional opioid receptors [120]. Activation of opioid receptors inhibits (acute) / superactivates (chronic) adenylate cyclase (AC) activity [121], impedes N- and L-type Ca²⁺ channels, increases phospholipase C activity, activates inwardly rectifying K⁺ channels, and turns on mitogen-activated protein kinases (MAPK) [122,123].

Estrogens, besides the well-established effects on female reproductive functions, exert various actions on the nervous system influencing pain sensation, mood, susceptibility to seizures, and neuroprotection against stroke damage and Alzheimer's disease [124]. Ovarian steroids have been found to modulate the activity of opioid receptors in healthy women and migraine sufferers [125], and replacement therapies through estrogens and progestagens could restore the activity of central opioid tonus in migraine patients [125]. Estrogen has also been demonstrated to decrease the secretion of β-endorphin, an endogenous opioid peptide, from the Ishikawa cells, an endometrial carcinoma cell line, in a concentration-and time-dependent manner [126]. The spinal KOR and DOR, but not MOR, activity is required for opioid-mediated elevations in maternal nociceptive thresholds, indicating the ability of estrogen to modulate spinal opioid antinociceptive activity [127].

Sexually dimorphic KOR-mediated antinociception has been demonstrated in antithetical antinociceptive/nociceptive responsiveness of female vs. males to KOR agonists-antagonists [128]. Compared to men, women reported greater analgesic effects from the mixed MOR/KOR ligands: pentazocine, nalbuphine and butorphanol [52,66]. In contrast, selective KOR agonists produced greater antinociceptive effects in male than female animals [129]. An animal study demonstrated that spinal morphine antinociception in females requires concomitant activation of MOR and KOR, and the expression of MOR/KOR heterodimers is more prominent in the spinal cord in females than males [130]. The same group further demonstrated that blockade of coexpressed ERα and GPR30, two types of estrogen receptors (detailed in the following section), substantially decreased MOR/KOR and eliminates mediation by KOR of spinal morphine antinociception, suggesting MOR/KOR could serve as a molecular target for analgesia in women [131] (Figure 1).

Figure 1

Schematic representation of the facilitation of KOR/MOR heterodimerization by E2. Biochemical and behavioral experiments suggest that ERs work cooperatively to increase KOR/MOR expression. We postulate that E2 triggers a signaling complex containing one or multiple ERs, which via an unknown mechanism enhances the formation of KOR/MOR heterodimers and thereby creates the sex difference in opioid actions. Modified from [131].

17β-estradiol (E2), the major ligand of estrogen receptors during reproductive years, rapidly attenuates the ability of μ-opioids to hyperpolarize guinea pig hypothalamic (β-endorphin, an opioid peptide) neurons. E2 does not compete for MOR or alter the affinity of MOR, but binds to a specific receptor that activates PKA to rapidly uncouple MOR from its K⁺ channel [132]. Increased PKA activity maintains cellular tolerance to MOR agonists in the hypothalamic arcuate nucleus (ARC) neurosecretory cells caused by chronic morphine treatment. Moreover, acute E2 and chronic opioid treatment attenuate MOR-mediated responses via a common PKA pathway [133]. Based on the high density of MOR, but the lack of effects of estrogen on [³⁵S]GTPyS binding, it is concluded that MOR interaction with its G-protein is not the target of estrogen's actions [134]. E2 may modulate the behavioral effects of cocaine by regulating MOR and KOR signaling in mesocorticolimbic brain structures in female rats [135]. In addition, sex-dependent differences have been found in the intake of ethanol in the absence of β-endorphins in mice [136], and in the regulation of gonadal hormone, DOR binding, and MOR density in the hippocampus by prenatal exposure to morphine in rats [137,138].

Multiple antinociceptive assays demonstrated that male rats are markedly more sensitive to morphine analgesia than females [128]. The difference cannot be attributed to gender-linked differences in serum levels of morphine after its injection [81], the acute effects of steroids [81], the pharmacokinetics of morphine [83], MOR number and the binding affinity of the MOR agonists [139], and morphine stimulation of G protein determined using GTPase and [³⁵S]GTPyS binding assays [139]. It is postulated that the organizational effects of steroids during critical periods in development, which determine gender-related distinctions, may be significant in the male-female differences [81]. Another explanation for this gender difference is that pathways downstream of MOR and G protein are more efficient in male rats than in female rats such that there is a larger receptor reserve for morphine-mediated antinociception [139]. One mystery that remains poorly understood is that many aspects of sexually dimorphic opioid responsiveness in humans are opposite to that observed in laboratory animals [128].

Opioid regulation of estrogen receptors

Estrogens act on two types of receptors, nuclear estrogen receptors (ERα and ERβ) and the membrane-associated estrogen G protein-coupled receptor (GPR30, also known as GPER). ERα and ERβ modulate the long-lasting effect of estrogen by regulating gene transcription, whereas GPR30 produces more rapid effects by generation of the secondary messengers and activation of receptor tyrosine kinases [140].

Estrogen promotes the growth and development of breast cancer via ER. ERα is the major ER in neoplastic breast epithelium, whereas ERβ is the predominant ER in normal breast tissue [141,142]. The MOR agonist morphine promotes tumor neovascularization in E2-dependent human breast tumor xenograft model, MCF-7 cell, in mice leading to increased tumor progression at medically relevant concentrations [143]. In contrast, the opioid receptor antagonist naloxone inhibits MCF-7 breast cancer growth in mice [144,145]. Naloxone modulates ERα activity directly as well as indirectly via MOR, suggesting that naloxone-like compounds can be developed as novel therapeutic molecules for breast cancer therapy [145]. Additionally, ERβ is expressed in human vascular endothelial cells, and morphine down-regulates this receptor as determined by real-time RT-PCR [146]. The DOR agonist SNC80 decrease anxiety- and depression-like behavior following withdrawal from chronic cocaine use in male rats [147], and may serve as a potential anxiolytic in females [148]. Further research focusing on the contribution of circulating hormones and DOR agonists on cocaine withdrawal-induced anxiety in females and understanding the sex differences is needed.

The regulatory actions of opioids on estrogen receptors have been described in breast cancer, yet never been linked to the sex differences in opioid analgesia and addiction. Significance of such opioid actions in the sex difference remains elusive, and may be explored both in vitro and in vivo. The in vitro assays can be done by applying the opioids to neuronal cells expressing specific estrogen receptors to characterize the cellular responses of the estrogen receptors. The in vivo assays measuring the extent of opioid analgesia and addiction in estrogen receptor knockout mice, with females of different stages of estrous cycle and males, should be performed. Specific antagonists to the opioid receptors should be applied to characterize the interacting opioid receptors.

Interactions among opioid and estrogen receptors

MOR internalization is correlated with MOR-mediated inhibition of lordosis [149]. MOR antagonists block receptor internalization and facilitate lordosis [149,150]. ERα, but not ERβ, is required for estrogen-induced MOR internalization, suggesting that ERα can mediate rapid actions of estrogen [151]. The mRNA of the ORL1 receptor, the non-canonical member of the opioid receptor family, is present in majority of ERα and/or ERβ mRNA-containing neurons, and the sex-related differences in the ORL1 gene expression in the trigeminal nucleus caudalis appear to be determined in part by estrogen levels [152].

GPR30, the plasma membrane ER, is expressed in pain-relevant areas of the rat central nervous system, and the expression levels are similar in the male and female [153 –156]. GPR30 activation leads to hyperalgesia in rats [157,158] and spinal nociception in mice [159], and is involved in mediating the rapid pronociceptive effects of E2 [155,157,160]. The downstream mechanisms involve cytosolic calcium increase [161,162], ROS accumulation [163], and neuronal membrane depolarization [159]. Stimulation of plasma membrane ERs is coupled to the activation of the same signaling molecules that participate in most membrane initiated signaling cascades as opioid receptors, e.g., protein kinase A, protein kinase B, protein kinase C, phospholipase C, inositol triphosphate, MAPK, ERK, tyrosine kinases, etc. [164 –180] Due to the overlapping of the secondary messenger pathways, activation of GPR30 by estrogen is postulated to influence the signaling cascades of the opioid receptors, leading to the sex differences in the effects of opioids because of different GPR30 expression patterns between males and females (Figure 2).

Figure 2

Diagram of the postulated cross-talk between estrogen and opioid receptors. Upon binding of the opioids, opioid receptors (OR) activate different intracellular signaling pathways through the G protein (composed of a, β and γ subunits). The activation of phospholipase C (PLC) catalyzes the hydrolysis of membrane-bound phosphatidylinositol 4, 5-bisphosphate (PIP₂) into inositol 1, 4, 5-trisphosphate (IP₃) and diacylglycerol (DAG). IP₃ induces calcium release from the endoplasmic reticulum that activates calcium-dependent signaling. DAG activates protein kinase C (PKC). PKC activates adenylate cyclase (AC), which increases cAMP production, and subsequently stimulates protein kinase A (PKA). PKA can phosphorylate various proteins including ion channels (L-type voltage-gated Ca²⁺ channels [L-VGCC], G protein-coupled inwardly rectifying K⁺ channels [GIRK], and small conductance Ca²⁺-dependent K⁺ channels [SK]) and cAMP-responsive element binding protein (CREB). The activation of the mitogen-activated protein kinase (MAPK) transduction cascades can stimulate multiple targets, including nuclear transcription factors (such as CREB), cytoplasmic enzymes (including tyrosine hydroxylase), cytoskeletal proteins, and ion channels. Estradiol (E2) can activate the membrane-bound estrogen receptor (mER) and modulate the ionic conductance through phosphorylation of ionotropic receptors or uncoupling of OR from their ionic channels or intracellular effectors. E2 can also bind to nuclear ER dimers and thereby bind to the estrogen-responsive element (ERE) on the DNA, resulting in the activation of specific gene transcription. Additionally, rapid effects of E2 mediated by mER can lead to CREB phosphorylation, altering gene transcription through the interaction with the cAMP responsive element (CRE). Modified from [181].

Although opioids and estrogen can activate common signaling pathways, there is no direct evidence that signaling crosstalk among estrogen and opioid receptors contributes to the sex differences in opioid analgesia and addiction. This data gap should be filled by performing assays measuring the extent of opioid analgesia and addiction in opioid receptor knockout mice, with males and females of different stages of estrous cycle. Specific antagonists to the estrogen receptors are required to identify the interacting estrogen receptors in the behavioral assays.

Conclusions

Although numerous reports have addressed gender differences of opioid receptor agonists, very few directly examined the mechanism. It has been proposed that differences in opioid receptor levels, distribution and efficiency of signaling and neural circuitry modulated by opioid receptor activation cause the sexual dimorphism [129]. However, direct evidence of the interactions among estrogen and opioid receptors is lacking. Animals deficient of estrogen receptors ERα, ERβ, or GPR30 lack the estrogen-regulated opioid effects, and hence display distinct analgesic and addictive responses to morphine. Functional interactions between estrogens and opioids should be investigated to provide the insight into gender differences in analgesia and addiction at both cellular and physiological levels. Male sex hormone such as testosterone may also play a role in opioid analgesia and addiction, as anabolic androgenic steroids have been shown to alter opioid receptor expression in SH-SY5Y human neuroblastoma cells [182]. This review focuses on estrogen receptors, but does not exclude the possibility that androgen receptors could cross-talk with opioid receptors and thereby contribute to the sex differences of opioid effects. Organismal factors must be considered when interpreting the data, since just as a male is not a female, a mouse is not a small rat, and a primate is not a human. Developmental stages, drug doses, routes of drug administration, types of assays employed, and genetic backgrounds should be considered and matched in future randomized clinical studies to define the sex differences in opioid analgesia and addiction.

Competing interests

Only the authors listed are responsible for the content and preparation of this manuscript. The authors declare no conflict of interest.

Authors' contributions

CW-SL drafted the manuscript and reviewed the literature. I-KH designed the review topic and helped write the manuscript. Both authors read the approved the final manuscript.

Footnotes

Abbreviations

Acknowledgements

Financial support for the preparation of this manuscript was provided by the National Health Research Institutes (PD-102-PP-16 and NHRI-102A1-PDCO-1312141) and China Medical University Hospital (DMR-101-123 and DMR-102-029).

References

Coluzzi

Pappagallo

National Initiative on Pain

: Opioid therapy for chronic noncancer pain: practice guidelines for initiation and maintenance of therapy. Minerva Anestesiol 2005, 71:425–433.

Ballantyne

: Opioid analgesia: perspectives on right use and utility. Pain Physician 2007, 10:479–491.

Whistler

: Examining the role of mu opioid receptor endocytosis in the beneficial and side-effects of prolonged opioid use: from a symposium on new concepts in mu-opioid pharmacology. Drug Alcohol Depend 2012, 121:189–204.

Portenoy

: Opioid therapy for chronic nonmalignant pain: a review of the critical issues. J Pain Symptom Manage 1996, 11:203–217.

Paulson

Minoshima

Morrow

Casey

: Gender differences in pain perception and patterns of cerebral activation during noxious heat stimulation in humans. Pain 1998, 76:223–229.

Manson

: Pain: sex differences and implications for treatment. Metabolism 2010, 59(Suppl 1)516–520.

Unruh

: Gender variations in clinical pain experience. Pain 1996, 65:123–167.

Back

Payne

Wahlquist

Carter

Stroud

Haynes

Hillhouse

Brady

Ling

: Comparative profiles of men and women with opioid dependence: results from a national multisite effectiveness trial. Am J Drug Alcohol Abuse 2011, 37:313–323.

SAMHSA: Results from the 2011 National Survey on Drug Use and Health: Mental Health Findings. Rockville, MD: NSDUH Series H-45, HHS Publication No. (SMA) 12–4725; 2011. USA: Substance Abuse and Mental Health Services Administration.

10.

Lynch

Roth

Carroll

: Biological basis of sex differences in drug abuse: preclinical and clinical studies. Psychopharmacology (Berl) 2002, 164:121–137.

11.

Carroll

Lynch

Roth

Morgan

Cosgrove

: Sex and estrogen influence drug abuse. Trends Pharmacol Sci 2004, 25:273–279.

12.

Hughes

Liu

Marquis

Muniz

Pangalos

Ring

Whiteside

Brandon

: Estrogen receptor neurobiology and its potential for translation into broad spectrum therapeutics for CNS disorders. Curr Mol Pharmacol 2009, 2:215–236.

13.

Andersson

Ejlertsson

Leden

Rosenberg

: Chronic pain in a geographically defined general population: studies of differences in age, gender, social class, and pain localization. Clin J Pain 1993, 9:174–182.

14.

Blyth

March

Brnabic

Jorm

Williamson

Cousins

: Chronic pain in Australia: a prevalence study. Pain 2001, 89:127–134.

15.

Buskila

Abramov

Biton

Neumann

: The prevalence of pain complaints in a general population in Israel and its implications for utilization of health services. J Rheumatol 2000, 27:1521–1525.

16.

Eriksen

Jensen

Sjogren

Ekholm

Rasmussen

: Epidemiology of chronic non-malignant pain in Denmark. Pain 2003, 106:221–228.

17.

Moulin

Clark

Speechley

Morley-Forster

: Chronic pain in Canada-prevalence, treatment, impact and the role of opioid analgesia. Pain Res Manag 2002, 7:179–184.

18.

Tsang

Von Korff

Lee

Alonso

Karam

Angermeyer

Borges

Bromet

Demytteneare

de Girolamo

: Common chronic pain conditions in developed and developing countries: gender and age differences and comorbidity with depression-anxiety disorders. J Pain 2008, 9:883–891.

19.

Fillingim

King

Ribeiro-Dasilva

Rahim-Williams

Riley

3rd : Sex, gender, and pain: a review of recent clinical and experimental findings. J Pain 2009, 10:447–485.

20.

Zimmer

Basler

Vedder

Lautenbacher

: Sex differences in Cortisol response to noxious stress. Clin J Pain 2003, 19:233–239.

21.

Riley

3rd Robinson

Wise

Myers

Fillingim

: Sex differences in the perception of noxious experimental stimuli: a meta-analysis. Pain 1998, 74:181–187.

22.

Garcia

Godoy-lzquierdo

Godoy

Perez

Lopez-Chicheri

: Gender differences in pressure pain threshold in a repeated measures assessment. Psychol Health Med 2007, 12:567–579.

23.

Chesterton

Barlas

Foster

Baxter

Wright

: Gender differences in pressure pain threshold in healthy humans. Pain 2003, 101:259–266.

24.

Fillingim

Maixner

Kincaid

Silva

: Sex differences in temporal summation but not sensory-discriminative processing of thermal pain. Pain 1998, 75:121–127.

25.

Nishino

Isono

Ishikawa

Shinozuka

: Sex differences in the effect of dyspnea on thermal pain threshold in young healthy subjects. Anesthesiology 2008, 109:1100–1106.

26.

Raak

Wahren

: Stress coping strategies in thermal pain sensitive and insensitive healthy subjects. Int J Nurs Pract 2001, 7:162–168.

27.

Racine

Tousignant-Laflamme

Kloda

Dion

Dupuis

Choiniere

: A systematic literature review of 10 years of research on sex/gender and experimental pain perception – part 1 : are there really differences between women and men? Pain 2012, 153:602–618.

28.

Edwards

Haythornthwaite

Sullivan

Fillingim

: Catastrophizing as a mediator of sex differences in pain: differential effects for daily pain versus laboratory-induced pain. Pain 2004, 111:335–341.

29.

Miaskowski

Levine

: Does opioid analgesia show a gender preference for females? Pain Forum 1999, 8:34–44.

30.

Chia

Chow

Hung

Liu

Ger

Wang

: Gender and pain upon movement are associated with the requirements for postoperative patient-controlled iv analgesia: a prospective survey of 2,298 Chinese patients. Can J Anaesth 2002, 49:249–255.

31.

Dahan

Kest

Waxman

Sarton

: Sex-specific responses to opiates: animal and human studies. Anesth Analg 2008, 107:83–95.

32.

Cepeda

Carr

: Women experience more pain and require more morphine than men to achieve a similar degree of analgesia. Anesth Analg 2003, 97:1464–1468.

33.

Aubrun

Salvi

Coriat

Riou

: Sex- and age-related differences in morphine requirements for postoperative pain relief. Anesthesiology 2005, 103:156–160.

34.

Colameco

Becker

Simpson

: Sex bias in the assessment of patient complaints. J Fam Pract 1983, 16:1117–1121.

35.

Bernstein

Kane

: Physicians' attitudes toward female patients. Med Care 1981, 19:600–608.

36.

Calderone

: The Influence of Gender on the Frequency of Pain and Sedative Medication Administered to Postoperative-Patients. Sex Roles 1990, 23:713–725.

37.

DuPont

: Profile of a heroin-addiction epidemic. N Engl J Med 1971, 285:320–324.

38.

Howard

: Is inhalant use a risk factor for heroin and injection drug use among adolescents in the United States? Addict Behav 2007, 32:265–281.

39.

Maremmani

Stefania

Pacini

Maremmani

Carlini

Golia

Deltito

Dell'Osso

: Differential substance abuse patterns distribute according to gender in heroin addicts. J Psychoactive Drugs 2010, 42:89–95.

40.

Kelly

Schwartz

O'Grady

Mitchell

Reisinger

Peterson

Agar

Brown

: Gender Differences Among In- and Out-of-Treatment Opioid-Addicted Individuals. Am J Drug Alcohol Abuse 2009, 35:38–42.

41.

De Wilde

Soyez

Broekaert

Rosseel

Kaplan

Larsson

: Problem severity profiles of substance abusing women in European Therapeutic Communities: influence of psychiatric problems. J Subst Abuse Treat 2004, 26:243–251.

42.

Zimmermann

Krenz

Bouchat

Favrat

Besson

Zullino

: Prevalence of social phobia in a clinical sample of drug dependent patients. J Affect Disord 2004, 83:83–87.

43.

Kecskes

Rihmer

Kiss

Sarai

Szabo

Kiss

: Gender differences in panic disorder symptoms and illicit drug use among young people in Hungary. Eur Psychiatry 2002, 17:29–32.

44.

Grilo

Martino

Walker

Becker

Edell

McGlashan

: Psychiatric comorbidity differences in male and female adult psychiatric inpatients with substance use disorders. Compr Psychiatry 1997, 38:155–159.

45.

Landheim

Bakken

Vaglum

: Gender differences in the prevalence of symptom disorders and personality disorders among poly-substance abusers and pure alcoholics. Substance abusers treated in two counties in Norway. Eur Addict Res 2003, 9:8–17.

46.

Anker

Carroll

: Females are more vulnerable to drug abuse than males: evidence from preclinical studies and the role of ovarian hormones. Curr Top Behav Neurosci 2011, 8:73–96.

47.

McQuay

Bullingham

Paterson

Moore

: Clinical effects of buprenorphine during and after operation. Br J Anaesth 1980, 52:1013–1019.

48.

Watson

McQuay

Bullingham

Allen

Moore

: Single-dose comparison of buprenorphine 0.3 and 0.6 mg i.v. given after operation: clinical effects and plasma concentration. Br J Anaesth 1982, 54:37–43.

49.

Bullingham

McQuay

Dwyer

Allen

Moore

: Sublingual buprenorphine used postoperatively: clinical observations and preliminary pharmacokinetic analysis. Br J Clin Pharmacol 1981, 12:117–122.

50.

Miller

Ernst

: Sex differences in analgesia: a randomized trial of mu versus kappa opioid agonists. South Med J 2004, 97:35–41.

51.

Sibille

Kindler

Glover

Gonzalez

Staud

Riley

3rd Fillingim

: Individual differences in morphine and butorphanol analgesia: a laboratory pain study. Pain Med 2011, 12:1076–1085.

52.

Gear

Miaskowski

Gordon

Paul

Heller

Levine

: Kappa-opioids produce significantly greater analgesia in women than in men. Nat Med 1996, 2:1248–1250.

53.

Zacny

Beekman

: The effects of a cold-water stimulus on butorphanol effects in males and females. Pharmacol Biochem Behav 2004, 78:653–659.

54.

Gourlay

Kowalski

Plummer

Cousins

Armstrong

: Fentanyl blood concentration-analgesic response relationship in the treatment of postoperative pain. Anesth Analg 1988, 67:329–337.

55.

Chang

Dai

Ger

Wong

Chan

Tsou

: Determinants of patient-controlled epidural analgesia requirements: a prospective analysis of 1753 patients. Clin J Pain 2006, 22:751–756.

56.

Tamsen

Bondesson

Dahlstrom

Hartvig

: Patient-controlled analgesic therapy, Part III: pharmacokinetics and analgesic plasma concentrations of ketobemidone. Clin Pharmacokinet 1982, 7:252–265.

57.

Mercadante

Casuccio

Agnello

Barresi

: Methadone response in advanced cancer patients with pain followed at home. J Pain Symptom Manage 1999, 18:188–192.

58.

Bennett

Batenhorst

Graves

Foster

Griffen

Wright

: Variation in postoperative analgesic requirements in the morbidly obese following gastric bypass surgery. Pharmacotherapy 1982, 2:50–53.

59.

Dahlstrom

Tamsen

Paalzow

Hartvig

: Patient-controlled analgesic therapy, Part IV: pharmacokinetics and analgesic plasma concentrations of morphine. Clin Pharmacokinet 1982, 7:266–279.

60.

Bahar

Rosen

Vickers

: Self-administered nalbuphine, morphine and pethidine. Comparison, by intravenous route, following cholecystectomy. Anaesthesia 1985, 40:529–532.

61.

Burns

Hodsman

McLintock

Gillies

Kenny

McArdle

: The influence of patient characteristics on the requirements for postoperative analgesia. A reassessment using patient-controlled analgesia. Anaesthesia 1989, 44:2–6.

62.

De Koek

Scholtes

: Postoperative P.C.A. in abdominal surgery. Analysis of 200 consecutive patients. Acta Anaesthesiol Belg 1991, 42:85–91.

63.

Tsui

Tong

Irwin

Chan

Yang

: The efficacy, applicability and side-effects of postoperative intravenous patient-controlled morphine analgesia: an audit of 1233 Chinese patients. Anaesth Intensive Care 1996, 24:658–664.

64.

Sidebotham

Dijkhuizen

Schug

: The safety and utilization of patient-controlled analgesia. J Pain Symptom Manage 1997, 14:202–209.

65.

Lehmann

Tenbuhs

: Patient-controlled analgesia with nalbuphine, a new narcotic agonist-antagonist, for the treatment of postoperative pain. Eur J Clin Pharmacol 1986, 31:267–276.

66.

Gear

Miaskowski

Gordon

Paul

Heller

Levine

: The kappa opioid nalbuphine produces gender- and dose-dependent analgesia and antianalgesia in patients with postoperative pain. Pain 1999, 83:339–345.

67.

Fillingim

Hastie

Ness

Glover

Campbell

Staud

: Sex-related psychological predictors of baseline pain perception and analgesic responses to pentazocine. Biol Psychol 2005, 69:97–112.

68.

Fillingim

Ness

Glover

Campbell

Price

Staud

: Experimental pain models reveal no sex differences in pentazocine analgesia in humans. Anesthesiology 2004, 100:1263–1270.

69.

Mogil

Wilson

Chesler

Rankin

Nemmani

Lariviere

Grace

Wallace

Kaplan

Staud

: The melanocortin-1 receptor gene mediates female-specific mechanisms of analgesia in mice and humans. Proc Natl Acad Sci U S A 2003, 100:4867–4872.

70.

Gear

Gordon

Heller

Paul

Miaskowski

Levine

: Gender difference in analgesic response to the kappa-opioid pentazocine. Neurosci Lett 1996, 205:207–209.

71.

Tamsen

Hartvig

Fagerlund

Dahlstrom

: Patient-controlled analgesic therapy. Part I: Pharmacokinetics of pethidine in the per- and postoperative periods. Clin Pharmacokinet 1982, 7:149–163.

72.

Bartok

Craft

: Sex differences in opioid antinociception. J Pharmacol Exp Ther 1997, 282:769–778.

73.

Terner

Barrett

Grossell

Picker

: Influence of gonadectomy on the antinociceptive effects of opioids in male and female rats. Psychopharmacology (Berl) 2002, 163:183–193.

74.

Cook

Barrett

Roach

Bowman

Picker

: Sex-related differences in the antinociceptive effects of opioids: importance of rat genotype, nociceptive stimulus intensity, and efficacy at the mu opioid receptor. Psychopharmacology (Berl) 2000, 150:430–442.

75.

Barrett

Cook

Terner

Craft

Picker

: Importance of sex and relative efficacy at the mu opioid receptor in the development of tolerance and cross-tolerance to the antinociceptive effects of opioids. Psychopharmacology (Berl) 2001, 158:154–164.

76.

Holtman

Jr Sloan

Jing

Wala

: Modification of morphine analgesia and tolerance by flumazenil in male and female rats. Eur J Pharmacol 2003, 470:149–156.

77.

Lomas

Barrett

Terner

Lysle

Picker

: Sex differences in the potency of kappa opioids and mixed-action opioids administered systemically and at the site of inflammation against capsaicin-induced hyperalgesia in rats. Psychopharmacology (Berl) 2007, 191:273–285.

78.

Thornton

Smith

: Characterization of neonatal rat fentanyl tolerance and dependence. J Pharmacol Exp Ther 1997, 281:514–521.

79.

Rodriguez

Carlos

Ortega

Suarez

Calvo

Lukas

: Sex specificity in methadone analgesia in the rat: a population pharmacokinetic and pharmacodynamic approach. Pharm Res 2002, 19:858–867.

80.

Baamonde

Hidalgo

Andres-Trelles

: Sex-related differences in the effects of morphine and stress on visceral pain. Neuropharmacology 1989, 28:967–970.

81.

Cicero

Nock

Meyer

: Gender-related differences in the antinociceptive properties of morphine. J Pharmacol Exp Ther 1996, 279:767–773.

82.

Cicero

Nock

O'Connor

Meyer

: Role of steroids in sex differences in morphine-induced analgesia: activational and organizational effects. J Pharmacol Exp Ther 2002, 300:695–701.

83.

Cicero

Nock

Meyer

: Sex-related differences in morphine's antinociceptive activity: relationship to serum and brain morphine concentrations. J Pharmacol Exp Ther 1997, 282:939–944.

84.

Badillo-Martinez

Kirchgessner

Butler

Bodnar

: Monosodium glutamate and analgesia induced by morphine. Test-specific effects. Neuropharmacology 1984, 23:1141–1149.

85.

Craft

Stratmann

Bartok

Walpole

King

: Sex differences in development of morphine tolerance and dependence in the rat. Psychopharmacology (Berl) 1999, 143:1–7.

86.

Craft

Lee

: NMDA antagonist modulation of morphine antinociception in female vs. male rats. Pharmacol Biochem Behav 2005, 80:639–649.

87.

South

Wright

Lau

Mather

Smith

: Sex-related differences in antinociception and tolerance development following chronic intravenous infusion of morphine in the rat: modulatory role of testosterone via morphine clearance. J Pharmacol Exp Ther 2001, 297:446–457.

88.

Kepler

Kest

Kiefel

Cooper

Bodnar

: Roles of gender, gonadectomy and estrous phase in the analgesic effects of intracerebroventricular morphine in rats. Pharmacol Biochem Behav 1989, 34:119–127.

89.

Krzanowska

Bodnar

: Morphine antinociception elicited from the ventrolateral periaqueductal gray is sensitive to sex and gonadectomy differences in rats. Brain Res 1999, 821:224–230.

90.

Islam

Cooper

Bodnar

: Interactions among aging, gender, and gonadectomy effects upon morphine antinociception in rats. Physiol Behav 1993, 54:45–53.

91.

Kasson

George

: Endocrine influences on the actions of morphine: IV. Effects of sex and strain. Life Sci 1984, 34:1627–1634.

92.

Krzanowska

Ogawa

Pfaff

Bodnar

: Reversal of sex differences in morphine analgesia elicited from the ventrolateral periaqueductal gray in rats by neonatal hormone manipulations. Brain Res 2002, 929:1–9.

93.

Mousavi

Shafaghi

Kobarfard

Jorjani

: Sex differences and role of gonadal hormones on glutamate level in the nucleus accumbens in morphine tolerant rats: a microdialysis study. Eur J Pharmacol 2007, 554:145–149.

94.

Terner

Barrett

Lomas

Negus

Picker

: Influence of low doses of naltrexone on morphine antinociception and morphine tolerance in male and female rats of four strains. Pain 2006, 122:90–101.

95.

Liu

von Gizycki

Gintzler

: Sexually dimorphic recruitment of spinal opioid analgesic pathways by the spinal application of morphine. J Pharmacol Exp Ther 2007, 322:654–660.

96.

Lomas

Picker

: Behavioral assessment of temporal summation in the rat: sensitivity to sex, opioids and modulation by NMDA receptor antagonists. Psychopharmacology (Berl) 2005, 180:84–94.

97.

Kavaliers

Innes

: Developmental changes in opiate-induced analgesia in deer mice: sex and population differences. Brain Res 1990, 516:326–331.

98.

Kavaliers

Innes

: Sex differences in the effects of neuropeptide FF and IgG from neuropeptide FF on morphine- and stress-induced analgesia. Peptides 1992, 13:603–607.

99.

Kavaliers

Innes

: Sex differences in the effects of Tyr-MIF-1 on morphine- and stress-induced analgesia. Peptides 1992, 13:1295–1297.

100.

Candido

Lutfy

Billings

Sierra

Duttaroy

Inturrisi

Yoburn

: Effect of adrenal and sex hormones on opioid analgesia and opioid receptor regulation. Pharmacol Biochem Behav 1992, 42:685–692.

101.

Kest

Wilson

Mogil

: Sex differences in supraspinal morphine analgesia are dependent on genotype. J Pharmacol Exp Ther 1999, 289:1370–1375.

102.

Grisel

Mogil

Belknap

Grandy

: Orphanin FQ acts as a supraspinal, but not a spinal, anti-opioid peptide. Neuroreport 1996, 7:2125–2129.

103.

Craft

Bernai

: Sex differences in opioid antinociception: kappa and ‘mixed action’ agonists. Drug Alcohol Depend 2001, 63:215–228.

104.

Terner

Lomas

Smith

Barrett

Picker

: Pharmacogenetic analysis of sex differences in opioid antinociception in rats. Pain 2003, 106:381–391.

105.

Lynch

Carroll

: Sex differences in the acquisition of intravenously self-administered cocaine and heroin in rats. Psychopharmacology (Berl’, 1999, 144:77–82.

106.

Carroll

Morgan

Lynch

Campbell

Dess

: Intravenous cocaine and heroin self-administration in rats selectively bred for differential saccharin intake: phenotype and sex differences. Psychopharmacology (Berl) 2002, 161:304–313.

107.

Cicero

Aylward

Meyer

: Gender differences in the intravenous self-administration of mu opiate agonists. Pharmacol Biochem Behav 2003, 74:541–549.

108.

Wetherington

: Sex differences and gonadal hormone influences in drug addiction and sexual behavior: progress and possibilities. Norm Behav 2010, 58:2–7.

109.

Kepler

Standifer

Paul

Kest

Pasternak

Bodnar

: Gender effects and central opioid analgesia. Pain 1991, 45:87–94.

110.

Ali

Sharif

Elkadi

: Sex differences and the effect of gonadectomy on morphine-induced antinociception and dependence in rats and mice. Clin Exp Pharmacol Physiol 1995, 22:342–344.

111.

Ratka

Simpkins

: Effects of estradiol and progesterone on the sensitivity to pain and on morphine-induced antinociception in female rats. Norm Behav 1991, 25:217–228.

112.

Chatterjee

Das

Banerjee

Ghosh

: Possible physiological role of adrenal and gonadal steroids in morphine analgesia. Eur J Pharmacol 1982, 77:119–123.

113.

Kasson

George

: Endocrine influences on the actions of morphine. I. Alteration of target gland hormones. J Pharmacol Exp Ther 1983, 224:273–281.

114.

Banerjee

Chatterjee

Ghosh

: Ovarian steroids and modulation of morphine-induced analgesia and catalepsy in female rats. Eur J Pharmacol 1983, 96:291–294.

115.

Borzan

Fuchs

: Organizational and activational effects of testosterone on carrageenan-induced inflammatory pain and morphine analgesia. Neuroscience 2006, 143:885–893.

116.

Stoffel

Ulibarri

Craft

: Gonadal steroid hormone modulation of nociception, morphine antinociception and reproductive indices in male and female rats. Pain 2003, 103:285–302.

117.

Dawson-Basoa

Gintzler

: Estrogen and progesterone activate spinal kappa-opiate receptor analgesic mechanisms. Pain 1996, 64:608–615.

118.

Claiborne

Nag

Mokha

: Activation of opioid receptor like-1 receptor in the spinal cord produces sex-specific antinociception in the rat: estrogen attenuates antinociception in the female, whereas testosterone is required for the expression of antinociception in the male. J Neurosci 2006, 26:13048–13053.

119.

Keffer

Evans

: Opioid receptors: from binding sites to visible molecules in vivo. Neuropharmacology 2009, 56(Suppl 1):205–212.

120.

Zaveri

: The nociceptin/orphanin FQ receptor (NOP) as a target for drug abuse medications. Curr Top Med Chem 2011, 11:1151–1156.

121.

Pierre

Eschenhagen

Geisslinger

Scholich

: Capturing adenylyl cyclases as potential drug targets. Nat Rev Drug Discov 2009, 8:321–335.

122.

Christie

: Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction. Br J Pharmacol 2008, 154:384–396.

123.

Law

Wong

Loh

: Molecular mechanisms and regulation of opioid receptor signaling. Annu Rev Pharmacol Toxicol 2000, 40:389–430.

124.

McEwen

: Invited review: Estrogens effects on the brain: multiple sites and molecular mechanisms. J Appl Physiol 2001, 91:2785–2801.

125.

Genazzani

Petraglia

Volpe

Facchinetti

: Estrogen changes as a critical factor in modulation of central opioid tonus: possible correlations with post-menopausal migraine. Cephalalgia 1985, 5(Suppl 2):212–214.

126.

Gravanis

Makrigiannakis

Stournaras

Margioris

: Interaction between steroid hormones and endometrial opioids. Ann N Y Acad Sci 1994, 734:245–256.

127.

Dawson-Basoa

Gintzler

: Involvement of spinal cord delta opiate receptors in the antinociception of gestation and its hormonal simulation. Brain Res 1997, 757:37–42.

128.

Gintzler

Liu

: Importance of sex to pain and its amelioration; relevance of spinal estrogens and its membrane receptors. Front Neuroendocrinal 2012, 33:412–424.

129.

Rasakham

Liu-Chen

: Sex differences in kappa opioid pharmacology. Life Sci 2011, 88:2–16.

130.

Chakrabarti

Liu

Gintzler

: Formation of mu-/kappa-opioid receptor heterodimer is sex-dependent and mediates female-specific opioid analgesia. Proc Natl Acad Sci U S A 2010, 107:20115–20119.

131.

Liu

Chakrabarti

Schnell

Wessendorf

Gintzler

: Spinal synthesis of estrogen and concomitant signaling by membrane estrogen receptors regulate spinal kappa- and mu-opioid receptor heterodimerization and female-specific spinal morphine antinociception. J Neurosci 2011, 31:11836–11845.

132.

Lagrange

Ronnekleiv

Kelly

: Modulation of G protein-coupled receptors by an estrogen receptor that activates protein kinase A. Mol Pharmacol 1997, 51:605–612.

133.

Wagner

Ronnekleiv

Kelly

: Protein kinase A maintains cellular tolerance to mu opioid receptor agonists in hypothalamic neurosecretory cells with chronic morphine treatment: convergence on a common pathway with estrogen in modulating mu opioid receptor/effector coupling. J Pharmacol Exp Ther 1998, 285:1266–1273.

134.

Cunningham

Fang

Selley

Kelly

: mu-Opioid agonist-stimulated [35S]GTPgammaS binding in guinea pig hypothalamus: effects of estrogen. Brain Res 1998, 791:341–346.

135.

Segarra

Agosto-Rivera

Febo

Lugo-Escobar

Menendez-Delmestre

Puig-Ramos

Torres-Diaz

: Estradiol: a key biological substrate mediating the response to cocaine in female rats. Norm Behav 2010, 58:33–43.

136.

Racz

Schurmann

Karpushova

Reuter

Cichon

Montag

Furst

Schutz

Franke

Strohmaier

: The opioid peptides enkephalin and beta-endorphin in alcohol dependence. Biol Psychiatry 2008, 64:989–997.

137.

Vathy

Rimanoczy

Slamberova

: Prenatal exposure to morphine differentially alters gonadal hormone regulation of delta-opioid receptor binding in male and female rats. Brain Res Bull 2000, 53:793–800.

138.

Slamberova

Rimanoczy

Bar

Schindler

Vathy

: Density of mu-opioid receptors in the hippocampus of adult male and female rats is altered by prenatal morphine exposure and gonadal hormone treatment. Hippocampus 2003, 13:461–471.

139.

Peckham

Barkley

Divin

Cicero

Traynor

: Comparison of the antinociceptive effect of acute morphine in female and male Sprague-Dawley rats using the long-lasting mu-antagonist methocinnamox. Brain Res 2005, 1058:137–147.

140.

Prossnitz

Arterburn

Sklar

: GPR30: A G protein-coupled receptor for estrogen. Mol Cell Endocrinol 2007, 265–266:138–142.

141.

Hall

Couse

Korach

: The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem 2001, 276:36869–36872.

142.

Khan

Rogers

Obando

Tamsen

: Estrogen receptor expression of benign breast epithelium and its association with breast cancer. Cancer Res 1994, 54:993–997.

143.

Gupta

Kshirsagar

Chang

Schwartz

Law

Yee

Hebbel

: Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. Cancer Res 2002, 62:4491–4498.

144.

Tegeder

Grosch

Schmidtko

Haussler

Schmidt

Niederberger

Scholich

Geisslinger

: G protein-independent G1 cell cycle block and apoptosis with morphine in adenocarcinoma cells: involvement of p53 phosphorylation. Cancer Res 2003, 63:1846–1852.

145.

Farooqui

Geng

Stephenson

Zaveri

Yee

Gupta

: Naloxone acts as an antagonist of estrogen receptor activity in MCF-7 cells. Mol Cancer Ther 2006, 5:611–620.

146.

Cadet

Mantione

Bilfinger

Stefano

: Morphine down regulates human vascular tissue estrogen receptor expression determined by real-time RT-PCR. Neuro Endocrinol Lett 2002, 23:95–100.

147.

Perrine

Sheikh

Nwaneshiudu

Schroeder

Unterwald

: Withdrawal from chronic administration of cocaine decreases delta opioid receptor signaling and increases anxiety- and depression-like behaviors in the rat. Neuropharmacology 2008, 54:355–364.

148.

Ambrose-Land

Sterling

Van Bockstaele

: Cocaine withdrawal-induced anxiety in females: impact of circulating estrogen and potential use of delta-opioid receptor agonists for treatment. J Neurosci Res 2010, 88:816–824.

149.

Sinchak

Micevych

: Progesterone blockade of estrogen activation of mu-opioid receptors regulates reproductive behavior. J Neurosci 2001, 21:5723–5729.

150.

Eckersell

Popper

Micevych

: Estrogen-induced alteration of mu-opioid receptor immunoreactivity in the medial preoptic nucleus and medial amygdala. J Neurosci 1998, 18:3967–3976.

151.

Micevych

Rissman

Gustafsson

Sinchak

: Estrogen receptor-alpha is required for estrogen-induced mu-opioid receptor internalization. J Neurosci Res 2003, 71:802–810.

152.

Flores

Shughrue

Petersen

Mokha

: Sex-related differences in the distribution of opioid receptor-like 1 receptor mRNA and colocalization with estrogen receptor mRNA in neurons of the spinal trigeminal nucleus caudalis in the rat. Neuroscience 2003, 118:769–778.

153.

Dun

Brailoiu

Gao

Brailoiu

Arterburn

Prossnitz

Oprea

Dun

: Expression of estrogen receptor GPR30 in the rat spinal cord and in autonomic and sensory ganglia. J Neurosci Res 2009, 87:1610–1619.

154.

Hazell

Yao

Roper

Prossnitz

O'Carroll

Lolait

: Localisation of GPR30, a novel G protein-coupled oestrogen receptor, suggests multiple functions in rodent brain and peripheral tissues. J Endocrinol 2009, 202:223–236.

155.

Liverman

Brown

Sandhir

McCarson

Berman

: Role of the oestrogen receptors GPR30 and ERalpha in peripheral sensitization: relevance to trigeminal pain disorders in women. Cephalalgia 2009, 29:729–741.

156.

Takanami

Sakamoto

Matsuda

Hosokawa

Nishi

Prossnitz

Kawata

: Expression of G protein-coupled receptor 30 in the spinal somatosensory system. Brain Res 2010, 1310:17–28.

157.

Kuhn

Dina

Goswami

Suckow

Levine

Hucho

: GPR30 estrogen receptor agonists induce mechanical hyperalgesia in the rat. Eur J Neurosci 2008, 27:1700–1709.

158.

Hsieh

Dun

Oprea

Wang

Luo

Lin

Chang

Lee

: Estrogen rapidly modulates 5-hydroxytrytophan-induced visceral hypersensitivity via GPR30 in rats. Gastroenterology 2009, 137:1040–1050.

159.

Deliu

Brailoiu

Arterburn

Oprea

Benamar

Dun

Brailoiu

: Mechanisms of G protein-coupled estrogen receptor-mediated spinal nociception. J Pain 2012, 13:742–754.

160.

Fehrenbacher

Loverme

Clarke

Hargreaves

Piomelli

Taylor

: Rapid pain modulation with nuclear receptor ligands. Brain Res Rev 2009, 60:114–124.

161.

Ariazi

Brailoiu

Yerrum

Shupp

Slifker

Cunliffe

Black

Donato

Arterburn

Oprea

: The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells. Cancer Res 2010, 70:1184–1194.

162.

Revankar

Cimino

Sklar

Arterburn

Prossnitz

: A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 2005, 307:1625–1630.

163.

Kim

Lee

Wang

Cui

Kim

Chung

: Mitochondrial Ca(2+) uptake is essential for synaptic plasticity in pain. J Neurosci 2011, 31:12982–12991.

164.

Aronica

Kraus

Katzenellenbogen

: Estrogen action via the cAMP signaling pathway: stimulation of adenylate cyclase and cAMP-regulated gene transcription. Proc Natl Acad Sci U S A 1994, 91:8517–8521.

165.

Broutman

Foy

Thompson

Baudry

: The tyrosine kinase and mitogen-activated protein kinase pathways mediate multiple effects of estrogen in hippocampus. Proc Natl Acad Sci USA 2000, 97:3602–3607.

166.

Cardona-Gomez

Mendez

Garcia-Segura

: Synergistic interaction of estradiol and insulin-like growth factor-I in the activation of PI3K/Akt signaling in the adult rat hypothalamus. Brain Res Mol Brain Res 2002, 107:80–88.

167.

Moss

: 17 beta-Estradiol potentiates kainate-induced currents via activation of the cAMP cascade. J Neurosci 1996, 16:3620–3629.

168.

Lieberherr

Grosse

Kachkache

Balsan

: Cell signaling and estrogens in female rat osteoblasts: a possible involvement of unconventional nonnuclear receptors. J Bone Miner Res 1993, 8:1365–1376.

169.

Marino

Pallottini

Trentalance

: Estrogens cause rapid activation of IP3-PKC-alpha signal transduction pathway in HEPG2 cells. Biochem Biophys Res Commun 1998, 245:254–258.

170.

Mendoza

Soler

Tesarik

: Nongenomic steroid action: independent targeting of a plasma membrane calcium channel and a tyrosine kinase. Biochem Biophys Res Commun 1995, 210:518–523.

171.

Minami

Oomura

Nabekura

Fukuda

: 17 beta-estradiol depolarization of hypothalamic neurons is mediated by cyclic AMP. Brain Res 1990, 519:301–307.

172.

Mobbs

Kaplitt

Kow

Pfaff

: PLC-alpha: a common mediator of the action of estrogen and other hormones? Mol Cell Endocrinol 1991, 80C187–C191.

173.

Nabekura

Oomura

Minami

Mizuno

Fukuda

: Mechanism of the rapid effect of 17 beta-estradiol on medial amygdala neurons. Science 1986, 233:226–228.

174.

Qiu

Bosch

Tobias

Grandy

Scanlan

Ronnekleiv

Kelly

: Rapid signaling of estrogen in hypothalamic neurons involves a novel G-protein-coupled estrogen receptor that activates protein kinase C. J Neurosci 2003, 23:9529–9540.

175.

Razandi

Pedram

Greene

Levin

: Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERalpha and ERbeta expressed in Chinese hamster ovary cells. Mol Endocrinol 1999, 13:307–319.

176.

Singh

Setalo

Jr Guan

Warren

Toran-Allerand

: Estrogen-induced activation of mitogen-activated protein kinase in cerebral cortical expiants: convergence of estrogen and neurotrophin signaling pathways. J Neurosci 1999, 19:1179–1188.

177.

Szego

Davis

: Adenosine 3′,5′-monophosphate in rat uterus: acute elevation by estrogen. Proc Natl Acad Sci U S A 1967, 58:1711–1718.

178.

Toran-Allerand

Singh

Setalo

Jr : Novel mechanisms of estrogen action in the brain: new players in an old story. Front Neuroendocrinal 1999, 20:97–121.

179.

Watters

Campbell

Cunningham

Krebs

Dorsa

: Rapid membrane effects of steroids in neuroblastoma cells: effects of estrogen on mitogen activated protein kinase signalling cascade and c-fos immediate early gene transcription. Endocrinology 1997, 138:4030–4033.

180.

Zhou

Watters

Dorsa

: Estrogen rapidly induces the phosphorylation of the cAMP response element binding protein in rat brain. Endocrinology 1996, 137:2163–2166.

181.

Cornil

Ball

Balthazart

: Functional significance of the rapid regulation of brain estrogen action: where do the estrogens come from? Brain Res 2006, 1126:2–26.

182.

Guarino

Spampinato

: Nandrolone decreases mu opioid receptor expression in SH-SY5Y human neuroblastoma cells. Neuroreport 2008, 19:1131–1135.